<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font6" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font7" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font8" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font9" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font10" size="6" family="GillSans" color="#000000"/>
	<fontspec id="font11" size="8" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font12" size="6" family="GillSans,Bold" color="#000000"/>
<text top="41" left="55" width="110" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Nuclear Receptor 2005, 3 :4<i>Nuclear Receptor</i></text>
<text top="41" left="370" width="184" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.nuclear-receptor.com/content/3/1/4</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="105" segment_no="12" tag_type="text">Page 2 of 7<b>3</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="106" segment_no="13" tag_type="text">(page number not for citation purposes)</text>
<text top="237" left="55" width="241" height="13" font="font4" id="p1_t5" reading_order_no="22" segment_no="5" tag_type="text">activated transcription factors. Ligands for PPAR α include</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="23" segment_no="5" tag_type="text">polyunsaturated fatty acids and the fibrate class of lipid-</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="24" segment_no="5" tag_type="text">lowering drugs [2]. It is expressed at high levels in several<i>(page number not for citation purposes)</i></text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="25" segment_no="5" tag_type="text">cell types involved in the atherosclerotic process [3], and</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="26" segment_no="5" tag_type="text">its activation has beneficial effects on plasma lipids,</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="27" segment_no="5" tag_type="text">endothelial function and markers of inflammation [4].</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="28" segment_no="5" tag_type="text">Thus, the PPARA gene is a strong candidate for a genetic</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="29" segment_no="5" tag_type="text">determinant of CVD risk in people with type 2 diabetes<a href="">2</a>]. It is expressed at high levels in several</text>
<text top="333" left="55" width="15" height="9" font="font4" id="p1_t13" reading_order_no="30" segment_no="5" tag_type="text">[5].<a href="">ess [3], and</a></text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="31" segment_no="7" tag_type="text">The PPARA gene has been screened for common variation</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="32" segment_no="7" tag_type="text">[6-8]. The most studied variant is the leucine 162 valine<a href="">4</a>].</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="33" segment_no="7" tag_type="text">(L162V) polymorphism, present at allele frequencies</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="34" segment_no="7" tag_type="text">between 5 and 10%, and situated in the DNA binding<i>PPARA </i></text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="35" segment_no="7" tag_type="text">domain. Functional studies have demonstrated that the</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="36" segment_no="7" tag_type="text">V162 allele is more active in vitro [7,9], and the V162 allele</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="37" segment_no="7" tag_type="text">has been associated with altered plasma lipid levels<a href="">[5].</a></text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="38" segment_no="7" tag_type="text">[6,8,10], delayed progression of angiographically deter-</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="39" segment_no="7" tag_type="text">mined CV disease in the Lopid Coronary Angiography<i>PPARA </i></text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="40" segment_no="7" tag_type="text">Trial (LOCAT), and reduced risk of ischemic heart disease</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="41" segment_no="7" tag_type="text">in the Second Northwick Park Heart Study (NPHS2) [11].<a href="">[6-8]. The most stud</a>ied variant is the leucine 162 valine</text>
<text top="484" left="55" width="241" height="13" font="font4" id="p1_t25" reading_order_no="42" segment_no="7" tag_type="text">A second, more common, G → C variant situated in intron</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="43" segment_no="7" tag_type="text">7 (G2528C) is in partial allelic association with the L162V</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="44" segment_no="7" tag_type="text">variant and shows opposing effects on cardiovascular risk</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="45" segment_no="7" tag_type="text">and cardiac growth [9,11]. Recently it has been demon-</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="46" segment_no="7" tag_type="text">strated that haplotypes of these variants in association<i>in vitro </i></text>
<text top="543" left="55" width="241" height="13" font="font4" id="p1_t30" reading_order_no="47" segment_no="7" tag_type="text">with a further A → C variant in intron 1 influence age of<a href="">[7,9</a>], and the V162 allele</text>
<text top="557" left="55" width="210" height="9" font="font4" id="p1_t31" reading_order_no="48" segment_no="7" tag_type="text">onset of type 2 and time to requiring insulin [12].</text>
<text top="237" left="313" width="241" height="13" font="font4" id="p1_t32" reading_order_no="49" segment_no="6" tag_type="text">PPAR α activators improve the dyslipidemia associated<a href="">[6,8,10</a>], delayed progression of angiographically deter-</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t33" reading_order_no="50" segment_no="6" tag_type="text">with type 2 diabetes and may be particularly beneficial in</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t34" reading_order_no="51" segment_no="6" tag_type="text">lowering risk of CVD in subjects with type 2 diabetes or</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t35" reading_order_no="52" segment_no="6" tag_type="text">metabolic syndrome [13]. We therefore investigated the<a href="">[11].</a></text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t36" reading_order_no="53" segment_no="6" tag_type="text">association between PPARA gene variation with risk of</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t37" reading_order_no="54" segment_no="6" tag_type="text">CVD and diabetes related traits in Caucasian subjects with</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t38" reading_order_no="55" segment_no="6" tag_type="text">type 2 diabetes participating in the prospective popula-</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t39" reading_order_no="56" segment_no="6" tag_type="text">tion-based Genetics of Diabetes Audit and Research in</text>
<text top="333" left="313" width="188" height="9" font="font4" id="p1_t40" reading_order_no="57" segment_no="6" tag_type="text">Tayside Scotland (Go-DARTS) study [14-16].</text>
<text top="357" left="313" width="36" height="10" font="font7" id="p1_t41" reading_order_no="58" segment_no="8" tag_type="title">Results<a href=""> [9,11</a>]. Recently it has been demon-</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t42" reading_order_no="59" segment_no="9" tag_type="text">The clinical characteristics of the genotyped cohort are</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t43" reading_order_no="60" segment_no="9" tag_type="text">shown in table 1. The allele frequencies of both polymor-</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t44" reading_order_no="61" segment_no="9" tag_type="text">phisms were consistent with those previously published</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t45" reading_order_no="62" segment_no="9" tag_type="text">for European non-diabetic populations (table 2). The two</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t46" reading_order_no="63" segment_no="9" tag_type="text">polymorphisms were both in Hardy-Weinberg equilib-<a href="">sulin [12].</a></text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t47" reading_order_no="64" segment_no="9" tag_type="text">rium and were in significant linkage disequilibrium D' =</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t48" reading_order_no="65" segment_no="9" tag_type="text">0.204 p =&lt; 0.00001. Estimated haplotype frequencies</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t49" reading_order_no="66" segment_no="9" tag_type="text">indicated very similar values with those previously pub-</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t50" reading_order_no="67" segment_no="9" tag_type="text">lished (table 3). There was little evidence that the geno-</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t51" reading_order_no="68" segment_no="9" tag_type="text">types either singly, or when included in the model</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t52" reading_order_no="69" segment_no="9" tag_type="text">together, were associated with blood pressure or lipid<a href=""> [13]. We th</a>erefore investigated the</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t53" reading_order_no="70" segment_no="9" tag_type="text">measurements (table 4). V162 was associated with a gen-</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t54" reading_order_no="71" segment_no="9" tag_type="text">erally more cardioprotective profile with V/V homozy-<i>PPARA </i></text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t55" reading_order_no="72" segment_no="9" tag_type="text">gotes having lower systolic and diastolic blood pressure,</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t56" reading_order_no="73" segment_no="9" tag_type="text">lower LDL cholesterol and higher HDL cholesterol than L/</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="74" segment_no="9" tag_type="text">L homozygotes, although none of these differences were</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t58" reading_order_no="75" segment_no="9" tag_type="text">significant. Conversely C2528 homozygotes had a small</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="76" segment_no="9" tag_type="text">but significantly higher total cholesterol and calculated<a href="">14-16].</a></text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="77" segment_no="9" tag_type="text">LDL cholesterol compared to G/G homozygotes. We also<b>Results</b></text>
<text top="87" left="55" width="213" height="7" font="font8" id="p1_t61" reading_order_no="2" segment_no="2" tag_type="title">Table 1: Clinical characteristics of the Go-DARTS cohort</text>
<text top="105" left="59" width="56" height="7" font="font9" id="p1_t62" reading_order_no="3" segment_no="3" tag_type="table">No of individuals<a href="">ble 1</a>. The allele frequencies of both polymor-</text>
<text top="105" left="309" width="56" height="7" font="font9" id="p1_t63" reading_order_no="4" segment_no="3" tag_type="table">1810 (54% male)</text>
<text top="115" left="59" width="89" height="7" font="font9" id="p1_t64" reading_order_no="5" segment_no="3" tag_type="table">Age at recruitment (years)<a href="">le 2). Th</a>e two</text>
<text top="115" left="309" width="32" height="7" font="font9" id="p1_t65" reading_order_no="6" segment_no="3" tag_type="table">63.1 (9.6)</text>
<text top="125" left="59" width="54" height="7" font="font9" id="p1_t66" reading_order_no="7" segment_no="3" tag_type="table">Age at diagnosis</text>
<text top="125" left="309" width="32" height="7" font="font9" id="p1_t67" reading_order_no="8" segment_no="3" tag_type="table">54.9 (9.0)</text>
<text top="135" left="59" width="83" height="8" font="font9" id="p1_t68" reading_order_no="9" segment_no="3" tag_type="table">Body Mass Index (kg/m 2 )</text>
<text top="136" left="309" width="32" height="7" font="font9" id="p1_t69" reading_order_no="10" segment_no="3" tag_type="table">30.5 (5.4)<a href="">3). The</a>re was little evidence that the geno-</text>
<text top="146" left="59" width="57" height="7" font="font9" id="p1_t70" reading_order_no="11" segment_no="3" tag_type="table">Insulin treatment</text>
<text top="146" left="309" width="40" height="7" font="font9" id="p1_t71" reading_order_no="12" segment_no="3" tag_type="table">839 (44.1%)</text>
<text top="156" left="59" width="56" height="7" font="font9" id="p1_t72" reading_order_no="13" segment_no="3" tag_type="table">Smoking History<a href="">4). V162</a> was associated with a gen-</text>
<text top="156" left="309" width="40" height="7" font="font9" id="p1_t73" reading_order_no="14" segment_no="3" tag_type="table">958 (50.4%)</text>
<text top="166" left="59" width="113" height="7" font="font9" id="p1_t74" reading_order_no="15" segment_no="3" tag_type="table">Prevalent cerebrovascular disease</text>
<text top="166" left="309" width="31" height="7" font="font9" id="p1_t75" reading_order_no="16" segment_no="3" tag_type="table">67 (3.5%)</text>
<text top="177" left="59" width="54" height="7" font="font9" id="p1_t76" reading_order_no="17" segment_no="3" tag_type="table">Prevalent angina</text>
<text top="177" left="309" width="36" height="7" font="font9" id="p1_t77" reading_order_no="18" segment_no="3" tag_type="table">178 (9.4%)</text>
<text top="187" left="59" width="101" height="7" font="font9" id="p1_t78" reading_order_no="19" segment_no="3" tag_type="table">Previous myocardial infarction</text>
<text top="187" left="309" width="40" height="7" font="font9" id="p1_t79" reading_order_no="20" segment_no="3" tag_type="table">323 (17.0%)</text>
<text top="209" left="59" width="290" height="7" font="font9" id="p1_t80" reading_order_no="21" segment_no="4" tag_type="text">Data shown are mean (SD) for continuous variables and n (%) for categorical variables.<b>Table 1: Clinical characteristics of the Go-DARTS cohort</b></text>
<text top="604" left="55" width="497" height="7" font="font8" id="p1_t81" reading_order_no="78" segment_no="10" tag_type="title">Table 2: PPARA genotype distribution and allele frequencies in the Go-DARTS cohort. The corresponding allele frequencies from the</text>
<text top="613" left="55" width="274" height="7" font="font8" id="p1_t82" reading_order_no="79" segment_no="10" tag_type="title">Second Northwick Park Heart Study (NPHS2) 11 is shown for comparison.</text>
<text top="631" left="261" width="5" height="7" font="font8" id="p1_t83" reading_order_no="80" segment_no="11" tag_type="table">n</text>
<text top="631" left="510" width="5" height="7" font="font8" id="p1_t84" reading_order_no="81" segment_no="11" tag_type="table">n</text>
<text top="654" left="84" width="25" height="7" font="font8" id="p1_t85" reading_order_no="82" segment_no="11" tag_type="table">L162V</text>
<text top="654" left="175" width="10" height="7" font="font9" id="p1_t86" reading_order_no="83" segment_no="11" tag_type="table">L/L</text>
<text top="654" left="255" width="16" height="7" font="font9" id="p1_t87" reading_order_no="84" segment_no="11" tag_type="table">1573</text>
<text top="654" left="331" width="31" height="7" font="font8" id="p1_t88" reading_order_no="85" segment_no="11" tag_type="table">G2528C</text>
<text top="654" left="423" width="12" height="7" font="font9" id="p1_t89" reading_order_no="86" segment_no="11" tag_type="table">GG</text>
<text top="654" left="504" width="16" height="7" font="font9" id="p1_t90" reading_order_no="87" segment_no="11" tag_type="table">1216</text>
<text top="664" left="174" width="11" height="7" font="font9" id="p1_t91" reading_order_no="88" segment_no="11" tag_type="table">L/V</text>
<text top="664" left="257" width="12" height="7" font="font9" id="p1_t92" reading_order_no="89" segment_no="11" tag_type="table">224</text>
<text top="664" left="423" width="12" height="7" font="font9" id="p1_t93" reading_order_no="90" segment_no="11" tag_type="table">GC</text>
<text top="664" left="506" width="12" height="7" font="font9" id="p1_t94" reading_order_no="91" segment_no="11" tag_type="table">529</text>
<text top="674" left="174" width="12" height="7" font="font9" id="p1_t95" reading_order_no="92" segment_no="11" tag_type="table">V/V</text>
<text top="674" left="259" width="8" height="7" font="font9" id="p1_t96" reading_order_no="93" segment_no="11" tag_type="table">13</text>
<text top="674" left="423" width="12" height="7" font="font9" id="p1_t97" reading_order_no="94" segment_no="11" tag_type="table">CC</text>
<text top="674" left="508" width="8" height="7" font="font9" id="p1_t98" reading_order_no="95" segment_no="11" tag_type="table">64</text>
<text top="684" left="255" width="16" height="7" font="font9" id="p1_t99" reading_order_no="96" segment_no="11" tag_type="table">1810</text>
<text top="684" left="504" width="16" height="7" font="font9" id="p1_t100" reading_order_no="97" segment_no="11" tag_type="table">1809</text>
<text top="695" left="64" width="69" height="7" font="font8" id="p1_t101" reading_order_no="98" segment_no="11" tag_type="table">Go-DARTS allele</text>
<text top="704" left="88" width="18" height="7" font="font8" id="p1_t102" reading_order_no="99" segment_no="11" tag_type="table">freq.<b>Table 2: </b></text>
<text top="695" left="230" width="67" height="7" font="font9" id="p1_t103" reading_order_no="100" segment_no="11" tag_type="table">0.069 (0.061–0.077)<i><b>PPARA </b></i></text>
<text top="695" left="479" width="67" height="7" font="font9" id="p1_t104" reading_order_no="101" segment_no="11" tag_type="table">0.182 (0.169–0.194)<b>genotype distribution and allele frequencies in the Go-DARTS cohort. The corresponding allele frequencies from the </b></text>
<text top="714" left="63" width="67" height="7" font="font8" id="p1_t105" reading_order_no="102" segment_no="11" tag_type="table">NPHS allele freq.<b>Second Northwick Park Heart Study (NPHS2)</b></text>
<text top="714" left="254" width="18" height="7" font="font9" id="p1_t106" reading_order_no="103" segment_no="11" tag_type="table">0.063<b>11 </b></text>
<text top="714" left="503" width="18" height="7" font="font9" id="p1_t107" reading_order_no="104" segment_no="11" tag_type="table">0.174<b>is shown for comparison.</b></text>
</page>
</pdf2xml>
